Cellectar Biosciences Stock Forecast, Price & News

-0.02 (-1.83 %)
(As of 07/27/2021 11:30 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume15,258 shs
Average Volume1.23 million shs
Market Capitalization$56.42 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Cellectar Biosciences logo

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.24 out of 5 stars

Medical Sector

968th out of 2,218 stocks

Pharmaceutical Preparations Industry

464th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

Is Cellectar Biosciences a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cellectar Biosciences stock.
View analyst ratings for Cellectar Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Cellectar Biosciences?

Wall Street analysts have given Cellectar Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectar Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,590,000 shares, an increase of 40.7% from the June 30th total of 1,130,000 shares. Based on an average daily volume of 772,300 shares, the days-to-cover ratio is presently 2.1 days. Approximately 3.4% of the company's shares are sold short.
View Cellectar Biosciences' Short Interest

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cellectar Biosciences

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03.
View Cellectar Biosciences' earnings history

How has Cellectar Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLRB stock has decreased by 39.4% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Shares of Cellectar Biosciences reverse split on the morning of Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CLRB?

3 analysts have issued 1 year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $5.50. On average, they expect Cellectar Biosciences' stock price to reach $4.25 in the next year. This suggests a possible upside of 289.9% from the stock's current price.
View analysts' price targets for Cellectar Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the following people:
  • Mr. James V. Caruso, Pres, CEO & Director (Age 62, Pay $807.5k)
  • Mr. Dov Elefant, VP & CFO (Age 54, Pay $450.99k)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 48, Pay $491.01k)
  • Dr. John E. Friend II, M.D., Chief Medical Officer (Age 51)
  • Gregory J. Lynch Esq., Sec.

Who are some of Cellectar Biosciences' key competitors?

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.09.

How much money does Cellectar Biosciences make?

Cellectar Biosciences has a market capitalization of $57.48 million. The biopharmaceutical company earns $-15,090,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does Cellectar Biosciences have?

Cellectar Biosciences employs 11 workers across the globe.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is

Where are Cellectar Biosciences' headquarters?

Cellectar Biosciences is headquartered at 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.